Aquestive Therapeutics, Inc. AQST Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 63.5%-4.9pp | 58.3%-10.6pp | 60.3%-9.1pp | 61.1%-7.4pp | 68.4%+8.2pp | |
| Operating margin | -111.2%-35.2pp | -159.5%-106pp | -128.6%-92.7pp | -119.2%-93.2pp | -75.9%-38.2pp | |
| Net margin | -137.1%-37.1pp | -188.1%-111pp | -158.9%-99.2pp | -147.4%-103pp | -100%-44.2pp | |
| EBITDA margin | -110.1%-35.4pp | -158.3%-106pp | -127.3%-93.2pp | -117.9%-93.8pp | -74.7%-39.3pp | |
| Free cash flow margin | -88.2%+2.3pp | -119%-56.6pp | -117.4%-59.0pp | -113.3%-70.7pp | -90.4%-38.8pp | |
| Returns | ||||||
| Return on assets | -56.6%-9.8pp | -64%-8.4pp | -50.4%-8.9pp | -61.6%-32.1pp | -46.8%-16.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×-0.1× | 0.3×-0.4× | 0.3×-0.4× | 0.4×-0.3× | 0.5×-0.1× | |
| Inventory turnover | 2.4×+0.1× | 3×+0.2× | 2.3×-0.2× | 2.3×-0.6× | 2.3×-0.5× | |
| Liquidity | ||||||
| Current ratio | 4.1×-0.8× | 3.1×-1.5× | 5.9×-0.4× | 3.5×-4.0× | 4.9×-1.4× | |
| Quick ratio | 3.8×-0.6× | 3×-1.4× | 5.6×-0.3× | 3.2×-3.8× | 4.5×-1.4× | |
| Cash ratio | 3.5×-0.3× | 2.5×-1.2× | 5×-0.1× | 2.6×-3.9× | 3.8×-1.5× | |
| Leverage | ||||||
| Debt-to-assets | 0.5×-0.1× | 0.4×-0.1× | 0.4×-0.1× | 0.6×+0.2× | 0.6×+0.2× | |
| Interest coverage | -5×-1.3× | -6.4×-3.6× | -5×-3.0× | -4.7×-3.1× | -3.7×-1.2× | |
| Per Share | ||||||
| Book value per share | -$0.28+56.5% | -$0.31+54.6% | -$0.04+92.5% | -$0.73-87.2% | -$0.64-29.4% | |
| Valuation | ||||||
| Market capitalization | $560.13M+73.5% | $788.14M+143% | $676.24M+49.1% | $318.84M+34.7% | $286.73M-25.2% | |
| Enterprise value | $513.76M+63.6% | $726.59M+139% | $606.83M+42.4% | $318.08M+61.0% | $277.97M-17.9% | |
| Price / sales | 11.1×+5.2× | 17.7×+12.1× | 15.6×+7.9× | 7.2×+3.2× | 5.3×-2.2× | |
| EV / sales | 10.2×+4.4× | 16.3×+11.0× | 14×+6.7× | 7.2×+3.8× | 5.1×-1.5× | |
| Free cash flow yield | -7.9%+7.3pp | -6.7%+4.3pp | -7.5%0.0pp | -15.7%-5.2pp | -17.1%-10.2pp | |
| Earnings yield | -12.3%+4.5pp | -10.6%+3.0pp | -10.2%-2.4pp | -20.4%-9.5pp | -18.9%-11.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aquestive Therapeutics, Inc.'s profit margins?
- Aquestive Therapeutics, Inc. (AQST) runs a 63.5% gross margin and a -111.2% operating margin, with a -137.1% net margin.
- Where do Aquestive Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Aquestive Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
